Your browser doesn't support javascript.
loading
Experimentally guided computational antibody affinity maturation with de novo docking, modelling and rational design.
Cannon, Daniel A; Shan, Lu; Du, Qun; Shirinian, Lena; Rickert, Keith W; Rosenthal, Kim L; Korade, Martin; van Vlerken-Ysla, Lilian E; Buchanan, Andrew; Vaughan, Tristan J; Damschroder, Melissa M; Popovic, Bojana.
Afiliação
  • Cannon DA; Department of Antibody Discovery and Protein Engineering, AstraZeneca, Cambridge, United Kingdom.
  • Shan L; Department of Antibody Discovery and Protein Engineering, AstraZeneca, Gaithersburg, Maryland, United States of America.
  • Du Q; Department of Antibody Discovery and Protein Engineering, AstraZeneca, Gaithersburg, Maryland, United States of America.
  • Shirinian L; Department of Antibody Discovery and Protein Engineering, AstraZeneca, Gaithersburg, Maryland, United States of America.
  • Rickert KW; Department of Antibody Discovery and Protein Engineering, AstraZeneca, Gaithersburg, Maryland, United States of America.
  • Rosenthal KL; Department of Antibody Discovery and Protein Engineering, AstraZeneca, Gaithersburg, Maryland, United States of America.
  • Korade M; Department of Oncology Research, AstraZeneca, Gaithersburg, Maryland, United States of America.
  • van Vlerken-Ysla LE; Department of Oncology Research, AstraZeneca, Gaithersburg, Maryland, United States of America.
  • Buchanan A; Department of Antibody Discovery and Protein Engineering, AstraZeneca, Cambridge, United Kingdom.
  • Vaughan TJ; Department of Antibody Discovery and Protein Engineering, AstraZeneca, Cambridge, United Kingdom.
  • Damschroder MM; Department of Antibody Discovery and Protein Engineering, AstraZeneca, Gaithersburg, Maryland, United States of America.
  • Popovic B; Department of Antibody Discovery and Protein Engineering, AstraZeneca, Cambridge, United Kingdom.
PLoS Comput Biol ; 15(5): e1006980, 2019 05.
Article em En | MEDLINE | ID: mdl-31042706
ABSTRACT
Antibodies are an important class of therapeutics that have significant clinical impact for the treatment of severe diseases. Computational tools to support antibody drug discovery have been developing at an increasing rate over the last decade and typically rely upon a predetermined co-crystal structure of the antibody bound to the antigen for structural predictions. Here, we show an example of successful in silico affinity maturation of a hybridoma derived antibody, AB1, using just a homology model of the antibody fragment variable region and a protein-protein docking model of the AB1 antibody bound to the antigen, murine CCL20 (muCCL20). In silico affinity maturation, together with alanine scanning, has allowed us to fine-tune the protein-protein docking model to subsequently enable the identification of two single-point mutations that increase the affinity of AB1 for muCCL20. To our knowledge, this is one of the first examples of the use of homology modelling and protein docking for affinity maturation and represents an approach that can be widely deployed.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Biologia Computacional / Afinidade de Anticorpos Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Biologia Computacional / Afinidade de Anticorpos Idioma: En Ano de publicação: 2019 Tipo de documento: Article